Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NEO-2734 by Epigene Therapeutics for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
NEO-2734 is under clinical development by Epigene Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to...